Sell signal watch: the push stalls
CRISPR Therapeutics slips 2.6% as the sell-off slows but sellers stay in control
Sell signal watch: the push stalls
Our view last week
After last week's 11.2% drop, CRISPR Therapeutics stock sheds another 10.4% and a fresh Sell signal triggers: price is now boxed in between the double bottom in the 48 area and the first resistance just above, in the 47.8 area. Signal strength hits the ceiling, 100 out of 100 — "downtrend making lower lows, pace holding" — on a highly volatile name. This week's technical analysis places CRISPR Therapeutics 6th among the 140 US sell signals; the quality band flags trading as not recommended.
This week's summary
CRISPR Therapeutics shares are slowing their slide: after two weeks of steep losses, this week's decline is just 2.6% and no new low was set. Signal strength drops to 46 out of 100, and this week's technical analysis shows sellers still dominant on the last bar, in a full distribution phase. The stock slips to 42nd among the 141 US sell signals: trading not recommended.
Sell signal in observation
·2nd week from start
·US stocks
·T2
·📅 Earnings · Aug 10
★ See Gold version →
IQS Phase
74
in tension
Signal Strength
46
isolated weekly drop
Sizing
REDUCED
Ranking
#42 / 141
US stocks sell signals
Trade P&L %
+2.60%
from signal to today
Rank position
ranks 42nd among the 141 sell signals for US stocks in our ranking, with a signal strength of 46 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly +0.92% · monthly +6.01%
CRSP belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content